Quick Answer
Kyverna Therapeutics, Inc. reported Operating Income of -$169.83 million for fiscal year 2025.
Kyverna Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$169.83M | -19.1% |
| 2024 | -$142.60M | -128.5% |
| 2023 | -$62.41M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$38.73M | +0.1% | +12.8% |
| June 30, 2025 | -$44.41M | -32.8% | +6.3% |
| March 31, 2025 | -$47.41M | -61.5% | -22.3% |
| September 30, 2024 | -$38.77M | -138.1% | -16.0% |
| June 30, 2024 | -$33.44M | -151.4% | -13.9% |
| March 31, 2024 | -$29.36M | -156.5% | -80.3% |
| September 30, 2023 | -$16.28M | — | -22.4% |
| June 30, 2023 | -$13.30M | — | -16.2% |
- Kyverna Therapeutics, Inc. showed a decrease of -19.1% in Operating Income compared to the prior fiscal year.
- Over the 2023–2025 period, Kyverna Therapeutics, Inc.’s operating income has declined by 172.1% (from -$62.41 million to -$169.83 million).
- The most recent figure is from Kyverna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: